Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway.

OBJECTIVES Non-alcoholic steatohepatitis (NASH) is a chronic liver disease histologically characterized by liver steatosis, hepatocellular injury, inflammation and fibrosis, resulting in cirrhosis and hepatocellular carcinoma, but effective measures and obvious pathogenesis for NASH remain elusive. Chrysin (CH) has been reported to have anti-inflammatory effects but shows lower bioavailability. METHODS In this study, a chrysin nanoliposome (CH-NL) was first prepared and characterized. Then, we used the methionine-choline-deficient (MCD) diet to induce a mouse model of NASH. Finally, the effects of CH and CH-NL on NASH were evaluated in the liver of NASH mice. KEY FINDINGS The results showed that CH or CH-NL significantly reduced the accumulation of lipids in hepatocytes, alleviated liver injury, decreased the generation of radical oxygen species, and attenuated the accumulation of collagen fibre in the liver of NASH mice. In addition, CH and its nano-liposomes markedly inhibited the production of inflammatory cytokines and inflammatory cell infiltration in the liver of NASH mice. Further studies found that CH-NL and CH-NL downregulated the MCD diet-induced activation of Toll-like receptor 4 (TLR4) signalling pathway in the liver of mice. CONCLUSIONS CH and its nanoliposome alleviated MCD diet-induced NASH in mice, which might be through inhibiting TLR4 signalling pathway.

[1]  M. Roden,et al.  Mitochondrial alterations in fatty liver diseases. , 2022, Journal of hepatology.

[2]  D. Brenner,et al.  Molecular and cellular mechanisms of liver fibrosis and its regression , 2020, Nature Reviews Gastroenterology & Hepatology.

[3]  Wen Liu,et al.  Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice , 2019, Cellular & Molecular Immunology.

[4]  M. Shariati,et al.  Chrysin: Pharmacological and therapeutic properties. , 2019, Life sciences.

[5]  C. Dinu‐Pîrvu,et al.  Pharmacokinetics of B-Ring Unsubstituted Flavones , 2019, Pharmaceutics.

[6]  Jun Yu,et al.  Bone marrow‐derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells , 2019, The Journal of pathology.

[7]  G. Liebisch,et al.  iPla2β deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[8]  X. Chen,et al.  Pathogenesis of and major animal models used for nonalcoholic fatty liver disease , 2019, The Journal of international medical research.

[9]  Z. Younossi Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[10]  G. Palladini,et al.  Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress , 2019, Canadian journal of gastroenterology & hepatology.

[11]  Sally A El Awdan,et al.  Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats. , 2019, Chemico-biological interactions.

[12]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[13]  F. Bessone,et al.  Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.

[14]  D. Schuppan,et al.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.

[15]  A. Garg,et al.  Development and evaluation of Chrysin-Phospholipid complex loaded solid lipid nanoparticles - storage stability and in vitro anti-cancer activity , 2018, Journal of microencapsulation.

[16]  Hao Zhou,et al.  Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy , 2018, Redox biology.

[17]  A. Feldstein,et al.  Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.

[18]  M. Konerman,et al.  Pharmacotherapy for NASH: Current and emerging. , 2018, Journal of hepatology.

[19]  G. Sulaiman,et al.  Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity , 2018, Artificial cells, nanomedicine, and biotechnology.

[20]  M. Yoneda,et al.  Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.

[21]  S. Rezaee,et al.  An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[23]  A. Bast,et al.  The potential of flavonoids in the treatment of non-alcoholic fatty liver disease , 2017, Critical reviews in food science and nutrition.

[24]  Abolfazl Akbarzadeh,et al.  Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications , 2017, Artificial cells, nanomedicine, and biotechnology.

[25]  N. Oku Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases. , 2017, Biological & pharmaceutical bulletin.

[26]  T. Giri,et al.  Nano-encapsulation of capsaicin on lipid vesicle and evaluation of their hepatocellular protective effect. , 2016, International journal of biological macromolecules.

[27]  A. Alanazi,et al.  Targeted nano-delivery of novel omega-3 conjugate against hepatocellular carcinoma: Regulating COX-2/bcl-2 expression in an animal model. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  U. Haberkorn,et al.  A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  Jianqing Gao,et al.  Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo , 2016, International journal of nanomedicine.

[30]  Alexis M. Kalergis,et al.  Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.

[31]  G. Musso,et al.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.

[32]  A. Hermenean,et al.  Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. , 2015, Chemico-biological interactions.

[33]  T. Pihlajaniemi,et al.  Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences , 2015, Redox biology.

[34]  J. Antoun,et al.  Hepatic TLR4 signaling in obese NAFLD. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[35]  J. González‐Gallego,et al.  Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy. , 2015, Current medicinal chemistry.

[36]  F. Tacke,et al.  Roles for chemokines in liver disease. , 2014, Gastroenterology.

[37]  Z. Gu,et al.  Nanoparticles generated by PEG-Chrysin conjugates for efficient anticancer drug delivery. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[38]  Zhiyuan Niu,et al.  Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARγ. , 2014, Biochemical pharmacology.

[39]  Zheng Zhang,et al.  The role of neutrophils in the development of liver diseases , 2014, Cellular and Molecular Immunology.

[40]  J. Odin,et al.  Toll‐like receptors and liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[41]  Rainer H Müller,et al.  Nanotoxicological classification system (NCS) - a guide for the risk-benefit assessment of nanoparticulate drug delivery systems. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  E. Seki,et al.  Toll‐like receptors in alcoholic liver disease, non‐alcoholic steatohepatitis and carcinogenesis , 2013, Journal of gastroenterology and hepatology.

[43]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[44]  S. Kim,et al.  Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. , 2009, Biochemical pharmacology.

[45]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[46]  T. Walle,et al.  Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones. , 2007, Biochemical pharmacology.

[47]  I. Leclercq,et al.  NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. , 2007, Journal of hepatology.

[48]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[49]  G. Jacquemin [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[50]  P. Halushka,et al.  Disposition and metabolism of the flavonoid chrysin in normal volunteers. , 2001, British journal of clinical pharmacology.

[51]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[52]  V. Natesan,et al.  Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. , 2018, Phytochemistry.

[53]  T. Ishida,et al.  Liposomal Delivery Systems: Design Optimization and Current Applications. , 2017, Biological & pharmaceutical bulletin.